Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Neurogen prepares new class of brain GABA receptor ligands

April 3, 1998

Neurex completes patient enrollment in ziconotide phase III trial

April 2, 1998

Recent data suggest mechanism of action of nefiracetam's beneficial effects on cognition

April 2, 1998

Schering-Plough presents new agents for cognitive disorders

April 2, 1998

Effects of MKC-242 on cholinergic neurons examined using in vivo microdialysis

April 1, 1998

MCI-225: neurochemical profile of a novel antidepressant

April 1, 1998

OPC-24439, a new sigma-receptor ligand, suppresses hippocampal neuronal activity

April 1, 1998

Synthelabo claims compounds with selective affinity for certain GABA-A receptors

April 1, 1998

NOS inhibitors claimed by Schering AG for CNS disorders

April 1, 1998

Zeneca in-licenses novel chiral anesthetic agent

April 1, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.